This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2016 by Academic Myeloma Consortium
Sponsor:
Collaborators:
Criterium, Inc.
Amgen
Celgene Corporation
Information provided by (Responsible Party):
Academic Myeloma Consortium
ClinicalTrials.gov Identifier:
NCT01464034
First received: October 19, 2011
Last updated: July 12, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2020
  Estimated Primary Completion Date: December 2019 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):